U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H14F2N2O5
Molecular Weight 268.2147
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEDAZURIDINE

SMILES

OC[C@H]1O[C@@H](N2CC[C@@H](O)NC2=O)C(F)(F)[C@@H]1O

InChI

InChIKey=VUDZSIYXZUYWSC-DBRKOABJSA-N
InChI=1S/C9H14F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4-7,14-16H,1-3H2,(H,12,17)/t4-,5-,6-,7-/m1/s1

HIDE SMILES / InChI
Cedazuridine is a specific cytidine deaminase (CDA) inhibitor that was approved in combination with decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS). It is known that decitabine is rapidly metabolized by CDA prior to reaching systemic circulation when administered orally. Thus, cedazuridine by inhibition of CDA increases systemic exposure of decitabine.

CNS Activity

Curator's Comment: Neither cedazuridine nor its metabolites cross the blood-brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P32320
Gene ID: 978.0
Gene Symbol: CDA
Target Organism: Homo sapiens (Human)
0.4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
INQOVI

Approved Use

INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-AmericanBritish subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Sample Use Guides

The recommended dosage of INQOVI is 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until disease progression or unacceptable toxicity. A complete or partial response may take longer than 4 cycles.
Route of Administration: Oral
Name Type Language
CEDAZURIDINE
USAN   INN  
Official Name English
CEDAZURIDINE [USAN]
Common Name English
(4R)-2'-DEOXY-2',2'-DIFLUORO-3,4,5,6-TETRAHYDROURIDINE
Systematic Name English
URIDINE, 2'-DEOXY-2',2'-DIFLUORO-3,4,5,6-TETRAHYDRO-, (4R)-
Systematic Name English
Cedazuridine [WHO-DD]
Common Name English
CEDAZURIDINE [ORANGE BOOK]
Common Name English
CEDAZURIDINE COMPONENT OF INQOVI
Brand Name English
E-7727
Code English
INQOVI COMPONENT CEDAZURIDINE
Brand Name English
ASTX-727 COMPONENT CEDAZURIDINE
Code English
E7727
Code English
ASTX727 COMPONENT CEDAZURIDINE
Code English
cedazuridine [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 697019
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
Code System Code Type Description
USAN
GH-142
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
PUBCHEM
25267009
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
INN
10741
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
CAS
1141397-80-9
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
SMS_ID
100000181098
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
NCI_THESAURUS
C164146
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
FDA UNII
39IS23Q1EW
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
RXCUI
2384449
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY
DAILYMED
39IS23Q1EW
Created by admin on Thu Jul 06 20:06:40 UTC 2023 , Edited by admin on Thu Jul 06 20:06:40 UTC 2023
PRIMARY